In the Original Investigation titled “Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer,”1 published May 3, 2021, there were errors in the x-axis tick labels in Figure 4. All of the labels were off by a factor of 10; for example, “6000” should have appeared as “60 000” and so forth along the entire x-axis. This article has been corrected.1
Errors in x-Axis Labeling in Figure. JAMA Netw Open. 2021;4(6):e2118586. doi:10.1001/jamanetworkopen.2021.18586
Customize your JAMA Network experience by selecting one or more topics from the list below.